Market Movers

Elevance Health, Inc.’s Stock Price Soars to $360.22, Marking a Robust 5.62% Increase: An Unmissable Investment Opportunity

By December 12, 2025 No Comments

Elevance Health, Inc. (ELV)

360.22 USD +19.18 (+5.62%) Volume: 2.98M

Explore Elevance Health, Inc.’s stock price performance, currently priced at $360.22 with a positive change of +5.62% this trading session. Despite a trading volume of 2.98M, ELV has seen a year-to-date decrease of -7.55%, reflecting its volatility in the market. Stay updated with ELV’s stock insights for smart investment decisions.


Latest developments on Elevance Health, Inc.

Elevance Health, Inc. made significant moves recently, with the appointment of Amy Schulman to its board, where she will join the Audit and Finance panels. The company’s stock, listed on the NYSE under ELV, outperformed its competitors on a strong trading day. This news was supported by a prior TD Cowen upgrade, and Baird adjusted its price target on Elevance Health to $340 from $297 while maintaining a neutral rating. Additionally, Elevance Health expanded its AI assistant access, which may impact investor response. The company’s strategic decisions and market outlook have been closely watched, with experts encouraging stockholders to inquire about ongoing investigations. With these developments, Elevance Health is positioning itself for potential growth in the healthcare sector.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars